See the DrugPatentWatch profile for bosentan

Bosentan is a medication used to treat pulmonary arterial hypertension (PAH) by relaxing and widening the blood vessels in the lungs, making it easier to breathe [1]. However, there are certain conditions under which bosentan should be discontinued.

According to the drug label, bosentan should be discontinued if a patient develops severe liver injury, as indicated by abnormal liver function tests and symptoms such as jaundice, dark urine, and bleeding [2]. Additionally, bosentan should be discontinued if a patient develops a serious blood disorder, such as a significant decrease in hemoglobin or red blood cell count, or if they develop severe skin reactions [2].

Furthermore, bosentan should be discontinued prior to surgery or any procedure that may cause bleeding [2]. This is because bosentan may increase the risk of bleeding, especially in patients with pre-existing bleeding disorders or those taking other medications that increase the risk of bleeding [2].

It is important to note that patients taking bosentan should have their liver function tested regularly, as liver injury can occur without symptoms [2]. Additionally, patients should inform their healthcare provider of any new symptoms or changes in their health while taking bosentan [2].

In summary, bosentan should be discontinued if a patient develops severe liver injury, a serious blood disorder, or severe skin reactions, or if they need to undergo surgery or a procedure that may cause bleeding.

Sources:
[1] "Bosentan: MedlinePlus Drug Information." MedlinePlus, U.S. National Library of Medicine, 15 Nov. 2021, medlineplus.gov/druginfo/meds/a605015.html.
[2] "Tracleer (bosentan) Tablets, for Oral Use [Prescribing Information]." Actelion Pharmaceuticals U.S., Inc., Jan. 2022, actelion.com/content/dam/actelion/us/pdfs/tracleer-pi.pdf.
[3] "Bosentan - Drug Patent Expiration & Patent Information." DrugPatentWatch, drugpatentwatch.com/drugs/bosentan.